What tumor types tend to have better uptake on fibroblast activation factor (FAP) labeled PET CT?
In PSMAfore, did Pluvicto improve overall survival when compared to switching to a different ARPI in patients with mCRPC who progressed on ADT and an ARPI?
Is there a dose-response relationship between focal boost dose and local control for prostate cancer?
In PSMAfore, did Pluvicto improve overall survival when compared to switching to a different ARPI in patients with mCRPC who progressed on ADT and an ARPI?
Is there a dose-response relationship between focal boost dose and local control for prostate cancer?
Answers
Sarcoma and pancreatic adenocarcinoma. These tumors have high stromal components with cancer associated fibroblasts or they may directly express FAP.
No. There was no improvement in OS, however 60% of patients in the ARPI arm crossed over to receive Pluvicto at progression.
Yes. 10-year outcomes from the FLAME trial showed a fairly steep dose response curve going from >20% local failure risk at GTV D98% of 77 Gy to <10% with a D98% over 90 Gy. | QuadShot News